Last updated: 11/03/2018 07:57:14
Treatment Of Hot Flashes/flushes In Postmenopausal Women (WARM study)
GSK study ID
105106
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 administered orally as monotherapy for 12 weeks in healthy postmenopausal women with moderate to extremely severe vasomotor symptoms
Trial description: The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Number of participants with adverse events (AE) and serious adverse events (SAE) and number of participants with mild, moderate and severe AE
Timeframe: Up to 21 weeks
Change from Baseline in vital signs of systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in vital sign of heart rate at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in Thyroid stimulating hormone (TSH) at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in thyroxine (T4) and insulin at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in fasting lipid profile at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in bi-layer endometrial thickness measured by transvaginal ultrasound (TVUS) or saline infusion sonohysterography (SIS)
Timeframe: Baseline (Week 0) to Week 12
Endometrial biopsy pathology
Timeframe: Baseline (Week 0) to Week 12
Occurrence of withdrawal bleeding-duration of spotting/bleeding
Timeframe: Up to Follow-up (Day 112)
Occurrence of withdrawal bleeding-number of days of spotting, number of days of bleeding, number of days of spotting/bleeding combined
Timeframe: Up to Follow-up (Day 112)
Mean change in frequency of Vasomotor symptoms (VMS) from Baseline at Week 12
Timeframe: Baseline (Week 0) and Week 12
Mean change in severity of VMS from Baseline at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in thrombotic marker- Fibrinogen at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in thrombotic marker- Tissue plasminogen activator (tPA) antigen at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline and Week 12 in inflammatory marker- High sensitivity C-reactive protein (hs-CRP) at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline and Week 12 in inflammatory marker- Endothelin-1 at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline and Week 12 in hematology parameter- Hematocrit at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in hematology parameter- Mean Corpuscle Hemoglobin (MCH) at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in hematology parameter- Mean Corpuscle Volume (MCV) at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in hematology parameter- Red blood cell (RBC) count at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in hematology parameters- Hemoglobin and Mean corpuscle hemoglobin concentration (MCHC) at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in hematology parameters- Basophils, eosinophils, lymphocytes, monocytes, platelet count, segmented neutrophils, total neutrophils and white blood cell (WBC) count at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in clinical chemistry parameters- Albumin and total protein at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in clinical chemistry parameters- Creatinine, direct bilirubin, total bilirubin and uric acid at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in clinical chemistry parameters- Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST) at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline in clinical chemistry parameters- Calcium, carbon dioxide (C02) content, chloride, phosphorous, inorganic, potassium, sodium and urea at Week 12
Timeframe: Baseline (Week 0) and Week 12
Secondary outcomes:
Mean change in frequency of VMS from Baseline to Weeks 4 and 8
Timeframe: Baseline (Week 0) to Week 8
Mean change in severity of VMS from Baseline to Weeks 4 and 8
Timeframe: Baseline (Week 0) to Week 8
Number of participants with VMS percent change from Baseline responders with a reduction in frequency at Week 12 of at least 50%, at least 75%, and 100%
Timeframe: Baseline (Week 0) and Week 12
Number of participants with VMS percent change from Baseline responders with a reduction in severity at Week 12 of at least 50%, at least 75%, and 100%
Timeframe: Baseline (Week 0) and Week 12
Change in Menopause Quality of Life (MENQoL) score from Baseline to Visits 6 (Week 4) and Visit 8 (Week 12)
Timeframe: Baseline (Week 0) to Week 12
Change in Medical Outcomes Study (MOS) Sleep score from Baseline to Visits 6 (Week 4) and Visit 8 (Week 12)
Timeframe: Baseline (Week 0) to Week 12
Changes in Vulvar vaginal atrophy (VVA) symptom score from Baseline to Visit 8 (Week 12)
Timeframe: Baseline (Week 0) to Visit 8 (Week 12)
Change in Brief Fatigue Inventory (BFI) score from Visit 2 to Visit 7
Timeframe: Visit 2 (Day -21) to Visit 7 (Week 8)
Change in the Centers for Epidemiologic Studies in Depression (CES-D) score from Visit 2 to Visit 7
Timeframe: Visit 2 (Day -21) to Visit 7 (Week 8)
Change in Work Productivity and Activity Impairment (WPAI) score from Visit 2 to Visit 7
Timeframe: Visit 2 (Day -21) to Visit 7 (Week 8)
Change from Visit 2 to Visit 8 in vaginal pH
Timeframe: Visit 2 (Day -21) to Visit 8 (Week 12)
Change from Visit 2 to Visit 8 in percentage of superficial cells to determine the Vaginal Maturation Index (VMI)
Timeframe: Visit 2 (Day -21) to Visit 8 (Week 12)
Change from Baseline in glucose at Week 12
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline at Week 12 in serum hormone levels- Estradiol
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline at Week 12 in serum hormone levels- Follicle stimulating hormone (FSH) and Luteinizing hormone (LH)
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline at Week 12 in serum hormone levels- Testosterone
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline at Week 12 in waist circumference
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline at Week 12 in hip circumference
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline at Week 12 in weight
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline at Week 12 in Body Mass Index (BMI)
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline at Week 12 in abdomen body circumference, abdomen saggital diameter and thigh circumference
Timeframe: Baseline (Week 0) and Week 12
Change from Baseline at Week 12 in abdomen visceral adipose tissue (AVAT), abdomen subcutaneous adipose tissue (ASAT), thigh subcutaneous adipose tissue (TSAT) and thigh intermuscular adipose tissue (TIAT)
Timeframe: Baseline (Week 0) and Week 12
Interventions:
Drug: Other: Placebo
Drug: GSK232802
Drug: PREMARIN
Enrollment:
356
Observational study model:
Not applicable
Primary completion date:
2008-23-07
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Menopausal and Female Climacteric States
Product
GSK232802
Collaborators
Not applicable
Study date(s)
July 2007 to July 2008
Type
Interventional
Phase
2
Participation criteria
Sex
Female
Age
40 - 65 years
Accepts healthy volunteers
No
- A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- Postmenopausal women aged 40 to 65 years old; postmenopausal defined as:
- A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- Investigator considers subject unfit for the study as a result of medical history, physical examination, or screening tests.
Inclusion and exclusion criteria
Inclusion criteria:
- A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- Postmenopausal women aged 40 to 65 years old; postmenopausal defined as: i.Amenorrheic for at least 12 consecutive months* OR ii.At least 6 weeks post-surgical bilateral oophorectomy† with or without hysterectomy. *Note: Although duration of amenorrhea is initially determined by subject history at the time of the screening visit (Visit 1), menopausal status must be confirmed by demonstrating levels of follicle stimulating hormone (FSH) >40 mIU/mL (SI: >40 IU/L) and estradiol <35pg/mL (SI: <128pmol/L) at entry. Screening reports provided by the Central Laboratory must be carefully reviewed to determine menopause eligibility prior to conducting Visit 2 assessments. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH and/or estradiol levels are not consistent with a post-menopausal condition, determination of subject eligibility should be discussed with the study medical monitor. †For women who are surgically menopausal, a copy of the pathology report or a statement on letterhead from the subject's physician documenting both ovaries have been removed or biochemical evidence of post-menopausal status as noted above is required prior to conducting Visit 2 assessments.
- A minimum average frequency of seven daily moderate to extremely severe hot flashes or episodes of night sweats sufficient to cause the patient to seek treatment (these episodes must be documented during the baseline period and the subject must have recorded frequency and severity of symptoms for a minimum of eight days in order to be eligible for randomization). This average frequency will be calculated by summing the number of moderate, severe, and extremely severe VMS events during the baseline period and dividing by the total number of non-missing days during this period, with details related to the definition of non-missing days described in Section 6.3.1.
- BMI within the range 19 to 35 kg/m2, inclusive.
- Subject has provided signed and dated written informed consent before admission to the study.
- Subject is able to understand and comply with the protocol requirements, instructions, and protocol-stated restrictions.
Exclusion criteria:
- A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- Investigator considers subject unfit for the study as a result of medical history, physical examination, or screening tests.
- Use of prescription or non-prescription drugs including: i.Hormone therapy (estrogen or estrogen/progestin combination or related products) within the following time period prior to conduct of Visit 1 assessments: -4 weeks for prior vaginal hormonal products (rings, creams, gels) or transdermal estrogen or estrogen/progestin products. -4 weeks for oral estradiol (e.g., micronized estradiol) or SERM products (e.g., raloxifene). -8 weeks for prior oral conjugated (equine or synthetic) estrogen or estrogen/progestin products or for prior intrauterine progestin therapy. -3 months for prior progestin implants or injectable estrogen. -6 months for prior estrogen pellet therapy or injectable progestin. ii.Use of putative therapies for VMS relief (e.g., selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], clonidine, gabapentin, tibolone, methyldopa, and the phytoestrogens black cohosh and red clover) within the past 30 days or 5 half-lives (whichever is longer) prior to conduct of Visit 1 assessments (note: half-lives will be provided in the SPM). Use of non-medication treatments for VMS, such as acupuncture and biofeedback, and other complementary or alternative therapies for VMS relief (with the exception of black cohosh and red clover which require a specified washout previously noted) must be discontinued at Visit 1. iii.Use of weight loss drugs (e.g., phentermine, sibutramine, orlistat, rimonabant) within 3 months of the first dose of investigational product. Other complementary or alternative therapies for weight reduction must be discontinued at Visit 1. See SPM for listing. iv.Use of pravastatin [Pravachol/Lipostat], rosuvastatin [Crestor], or pitavastatin [Livalo] within the past 30 days or 5 half-lives (whichever is longer) of the first dose of investigational product (note: half-lives will be provided in the SPM. Uses of other statins, for example simvastatin [Zocor], atorvastatin [Lipitor], fluvastatin [Lescol], lovastatin [Mevacor] is allowed). v.Use of bupropion, orphenadrine [Norflex], cyclophosphamide, efavirenz, ifosfamide, or methadone (because of the potential for GSK232802 to inhibit CYP2B6), or use of paclitaxel, torsemide, amodiaquine, repaglinide, rosiglitazone, or pioglitazone (because of the potential for GSK232802 to inhibit CYP2C8) within the past 30 days or 5 half-lives (whichever is longer) of the first dose of investigational product (note: half-lives will be provided in the SPM). Please note: Regardless of the reason for prescribing, use of the medications and therapies defined within Exclusion 2 above is prohibited. Concurrent administration of anti-depressants, anti-hypertensives, lipid-lowering therapies, etc. not specifically excluded above is allowed. See SPM for detailed listings and relevant half lives.
- Use of investigational drug within the past 30 days or 5 half-lives (whichever is longer) before the first dose of investigational product.
- Uterine disease or medical condition including: -Bi-layer endometrial thickness greater than 5mm as determined by TVUS, or for women with a non-informative TVUS, a single layer thickness of greater than 3 mm determined by SIS; presence of fibroids that obscure evaluation of endometrium by TVUS; -History of uterine cancer; evidence of endometrial hyperplasia or cancer as assessed by a screening endometrial biopsy. (Note: if a subject has insufficient tissue for diagnosis at screening, but bi-layer endometrial thickness by TVUS is ≤5mm or single wall thickness by SIS is ≤3mm, she may still be eligible for study entry if she meets the remaining inclusion/exclusion criteria); -Evidence of an endometrial polyp with hyperplastic or malignant epithelium; -Unexplained or unusual endometrial bleeding; or uterine surgery (other than hysterectomy*) within the past 6 months; *Note: hysterectomy must have been conducted at least 6 weeks prior to screening Visit 1. See also Inclusion criterion 1. -Abnormal cervical Pap smear with evidence of cervical dysplasia greater than or equal to low grade squamous intraepithelial lesion (LSIL) or with a diagnosis of atypical squamous cells of undetermined significance (ASCUS) that is HPV High Risk positive, or glandular lesions including but not limited to atypical glandular cells of undetermined significance (AGUS), adenocarcinoma in situ (AIS) or malignancy
- History of breast or ovarian cancer. Any clinically significant findings on mammography suspicious of breast malignancy that would require additional clinical testing to rule out breast cancer (note: simple cysts confirmed by ultrasound are allowed). Note: A screening mammogram is required unless the subject has had a mammogram performed within the last 12 months. If local mammography or medical management guidelines restrict the frequency with which mammograms can be performed, or impose age restrictions on the use of mammography, such that a subject may be unable to undergo the study-required screening mammogram, then these subjects must not be enrolled in the study. See Section 6.2.7.
- Cardiovascular conditions including: i. Systolic blood pressure (BP) outside the range 80 to 150 mmHg, diastolic BP outside the range 50 to 90 mmHg, and/or heart rate outside the range 40 to 100 bpm. Subjects with mild to moderate hypertension who are controlled on a stable antihypertension regimen may be enrolled if they meet the inclusion/exclusion criteria. ii. Symptomatic or asymptomatic arrhythmia of any clinical significance. iii. Any clinically significant abnormality identified on the screening 12-lead ECG. Subjects with QTc prolongation (QTc interval >450msec) will be excluded. iv. Has a documented history (within the last year) of myocardial infarction, angina, or has undergone coronary artery bypass surgery and/or percutaneous transluminal coronary angioplasty (PTCA). v. History of venous or arterial thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, stroke), history of known coagulopathy or abnormal coagulation factors; increased thrombotic risk as evidenced by positive APC resistance (APCR) evaluated at screening.
- Has a documented history of hepatobiliary disease or hepatic enzyme elevation including any one of the following: i.ALT or direct (conjugated) bilirubin values 1.5-fold higher than the ULN at screening. ii.Fasting triglycerides >400mg/dL (SI: >4.52mmol/L) at screening. If a subject is receiving a lipid-lowering therapy, then she must be on a stable dose for at least 1 month before screening.
- Has an abnormal thyroid function test assessed by TSH at screening (TSH <0.1uU/mL or >10uU/mL [SI: <0.1mU/L or >10mU/L] ). Note: If the TSH is mildly out of range at screening (TSH < 15U/mL), the subject may have her dose adjusted (if already on exogenous therapy) or have therapy initiated as deemed appropriate by the subject's physician, followed by a 3-4 week period to allow adequate equilibration. The TSH may then be re-assayed for eligibility purposes after this stabilization period has been completed. The subject should not progress through subsequent V2 assessments until re-assay demonstrates the TSH is within acceptable protocol-defined limits. Subjects with suppressed levels of TSH, <0.1U/mL, may have dose adjustment if free T4 is in normal range, and they are on exogenous thyroxine therapy.
- Has either a previous disease or current medical condition, which as judged by the investigator, may affect the interpretation of efficacy or safety data or which otherwise contraindicates participation in a clinical study with a new chemical entity. These diseases include, but are not limited to, cardiovascular disease, malignancy*, complex ovarian pathology, hepatic disease, renal disease, hematological disease, neurological disease, or endocrine disease. A subject with diabetes may be included if her diabetes is well controlled (i.e., HbA1c level is less than 8% at screening). *Note: Any history of malignancy within the past 5 years is exclusionary with the exception of basal cell (excluded if within the prior 2 years) or squamous cell (excluded if within the prior one year) carcinoma of the skin. Subjects with a prior malignancy who have had no evidence of disease for at least the past 5 years are eligible. Note that this timeframe does not apply to uterine, breast, and ovarian cancers which are defined in Exclusions 4 and 5 above.
- History of alcohol or substance abuse or dependence in the 12 months before screening as determined by the investigator.
- Positive results for hepatitis B surface antigen or hepatitis C antibodies as evaluated at screening Visit 1. Known history of HIV.
- Donation of blood in excess of 500mL within a 56-day period before screening.
- History or presence of allergy to the investigational product or drugs of this class (e.g., raloxifene), or history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
Trial location(s)
Location
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Argentina, 1012
Status
Study Complete
Location
GSK Investigational Site
Albuquerque, New Mexico, United States, 87106
Status
Study Complete
Location
GSK Investigational Site
Manchester, Lancashire, United Kingdom, M15 6SX
Status
Study Complete
Location
GSK Investigational Site
Wheat Ridge, Colorado, United States, 80043
Status
Study Complete
Location
GSK Investigational Site
Oxford, Oxfordshire, United Kingdom, OX3 9DU
Status
Study Complete
Location
GSK Investigational Site
Poway, California, United States, 92064
Status
Study Complete
Location
GSK Investigational Site
Aurora, Colorado, United States, 80012
Status
Study Complete
Location
GSK Investigational Site
Cambridge, Cambridgeshire, United Kingdom, CB2 2GG
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Louisville, Kentucky, United States, 40291
Status
Study Complete
Location
GSK Investigational Site
Harrow, Middlesex, United Kingdom, HA1 3UJ
Status
Study Complete
Location
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39122
Status
Study Complete
Location
GSK Investigational Site
Washington, District of Columbia, United States, 20036
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92103
Status
Study Complete
Location
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599-7570
Status
Study Complete
Location
GSK Investigational Site
Billings, Montana, United States, 59102
Status
Study Complete
Location
GSK Investigational Site
Denver, Colorado, United States, 80202
Status
Study Complete
Location
GSK Investigational Site
Sunset, Louisiana, United States, 70584
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Glendale, Arizona, United States, 85308
Status
Study Complete
Location
GSK Investigational Site
Muenster, Nordrhein-Westfalen, Germany, 48149
Status
Study Complete
Location
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1117ABH
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Albuquerque, New Mexico, United States, 87102
Status
Study Complete
Location
GSK Investigational Site
Waterloo, Liverpool, United Kingdom, L22 0LG
Status
Study Complete
Location
GSK Investigational Site
Nordhausen, Thueringen, Germany, 99734
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89119
Status
Study Complete
Location
GSK Investigational Site
Buckshaw Village, Chorley, Lancashire, United Kingdom, PR7 7NA
Status
Study Complete
Location
GSK Investigational Site
Chandler, Arizona, United States, 85225
Status
Study Complete
Location
GSK Investigational Site
Crystal River, Florida, United States, 34429
Status
Study Complete
Location
GSK Investigational Site
Overland Park, Kansas, United States, 66202
Status
Study Complete
Location
GSK Investigational Site
Portland, Oregon, United States, 97205
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45249
Status
Study Complete
Location
GSK Investigational Site
Subiaco, Western Australia, Australia, 6008
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92108
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30328
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Fort Myers, Florida, United States, 33916
Status
Study Complete
Location
GSK Investigational Site
Auchenflower, Queensland, Australia, 4066
Status
Study Complete
Location
GSK Investigational Site
Hilton Head Island, South Carolina, United States, 29926
Status
Study Complete
Location
GSK Investigational Site
Norfolk, Virginia, United States, 23507
Status
Study Complete
Location
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1128AAF
Status
Terminated/Withdrawn
Location
GSK Investigational Site
St Clair Shores, Michigan, United States, 48081
Status
Study Complete
Location
GSK Investigational Site
Buenos Aries, Buenos Aires, Argentina, C1425AWC
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19114
Status
Study Complete
Location
GSK Investigational Site
Nedlands, Western Australia, Australia, 6009
Status
Study Complete
Location
GSK Investigational Site
Savannah, Georgia, United States, 31405
Status
Study Complete
Location
GSK Investigational Site
Kippa Ring, Queensland, Australia, 4021
Status
Study Complete
Location
GSK Investigational Site
New Brunswick, New Jersey, United States, 08901
Status
Study Complete
Location
GSK Investigational Site
Scottsdale, Arizona, United States, 85251
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89146
Status
Study Complete
Location
GSK Investigational Site
Dulwich, South Australia, Australia, 5065
Status
Study Complete
Location
GSK Investigational Site
Boulder, Colorado, United States, 80301
Status
Study Complete
Location
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30159
Status
Study Complete
Location
GSK Investigational Site
Pinellas Park, Florida, United States, 33781
Status
Study Complete
Location
GSK Investigational Site
Tacoma, Washington, United States, 98405
Status
Study Complete
Location
GSK Investigational Site
Seattle, Washington, United States, 98105
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32259
Status
Study Complete
Location
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39112
Status
Study Complete
Location
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina, 1425
Status
Terminated/Withdrawn
Study documents
No study documents available.
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2008-23-07
Actual study completion date
2008-23-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website